Alnylam’s First Profitable Year Tests Durability Of TTR RNAi Franchise

Simply Wall St.

Feb 18

Alnylam Pharmaceuticals (NasdaqGS:ALNY) reports its first full year of profitability, supported by its TTR franchise. The company introduces a new RNAi manufacturing platform aimed at supporting its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612128394"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612128394\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612128394?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-18 16:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612128394","market":"nz","top_or_hot":-1,"title":"Alnylam’s First Profitable Year Tests Durability Of TTR RNAi Franchise","media":"Simply Wall St.","content":"<div>\n<p>Alnylam Pharmaceuticals (NasdaqGS:ALNY) reports its first full year of profitability, supported by its TTR franchise. The company introduces a new RNAi manufacturing platform aimed at supporting its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylams-first-profitable-year-tests-durability-of-ttr-rnai\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam’s First Profitable Year Tests Durability Of TTR RNAi Franchise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam’s First Profitable Year Tests Durability Of TTR RNAi Franchise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-18 16:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylams-first-profitable-year-tests-durability-of-ttr-rnai><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alnylam Pharmaceuticals (NasdaqGS:ALNY) reports its first full year of profitability, supported by its TTR franchise. The company introduces a new RNAi manufacturing platform aimed at supporting its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylams-first-profitable-year-tests-durability-of-ttr-rnai\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylams-first-profitable-year-tests-durability-of-ttr-rnai","article_id":"2612128394","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylams-first-profitable-year-tests-durability-of-ttr-rnai","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612128394","pubTimestamp":1771403539,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Alnylam Pharmaceuticals (NasdaqGS:ALNY) reports its first full year of profitability, supported by its TTR franchise.\nThe company introduces a new RNAi manufacturing platform aimed at supporting its growing portfolio of RNA targeted medicines.\nAlnylam enters new industry partnerships that expand its presence across RNA therapeutics and drug discovery.\n\nFor investors watching RNA based medicines, Alnylam sits at the center of a maturing part of biotech with an approved TTR franchise and a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","ALNY":"阿尔尼拉姆制药公司","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4505":"高瓴资本持仓","LU0882574055.USD":"富达全球健康医疗A ACC","RNA":"Avidity Biosciences, Inc.","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC"},"translate_title":"Alnylam的第一个盈利年测试了TTR RNAi特许经营权的持久性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":0.87,"ALNY":0.9},"content_text":"Alnylam Pharmaceuticals (NasdaqGS:ALNY) reports its first full year of profitability, supported by its TTR franchise. The company introduces a new RNAi manufacturing platform aimed at supporting its growing portfolio of RNA targeted medicines. Alnylam enters new industry partnerships that expand its presence across RNA therapeutics and drug discovery.  For investors watching RNA based medicines, Alnylam sits at the center of a maturing part of biotech with an approved TTR franchise and a growing commercial footprint. The shift to full year profitability adds a new dimension to the story, as the company now pairs a commercial revenue base with a broader RNAi platform and manufacturing capabilities. Looking ahead, the combination of internal platform development and external partnerships could influence how Alnylam allocates capital between R&D, manufacturing and potential new indications. For investors, the key questions include how durable the TTR franchise proves to be and how effectively the company turns its RNAi expertise into a broader, sustainable product lineup. Stay updated on the most important news stories for Alnylam Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Alnylam Pharmaceuticals. NasdaqGS:ALNY Earnings & Revenue Growth as at Feb 2026 4 things going right for Alnylam Pharmaceuticals that this headline doesn't cover. Alnylam’s first full year of profitability, with 2025 net income of US$313.75 million on revenue of US$3.71b, shows that its RNAi model is starting to scale commercially rather than relying only on upfronts and milestones. For you as an investor, that matters because it suggests the TTR franchise, including Amvuttra’s expanded ATTR-CM indication, is now big enough to cover a still-heavy R&D bill while funding a broader RNA-targeted portfolio. The new RNAi manufacturing platform points to a push for more control over cost of goods and capacity, which can be important if volumes rise or if pricing pressure builds across rare disease drugs. AdvertisementHow This Fits Into The Alnylam Pharmaceuticals Narrative  The step into full-year profitability alongside strong TTR contribution aligns with the narrative that growing adoption of core RNAi therapies and operational leverage can support revenue growth and margin improvement. At the same time, the earnings mix reinforces how dependent Alnylam still is on a single franchise, which ties back to concerns about revenue concentration and potential margin pressure if competition in TTR amyloidosis intensifies. The move to a new RNAi manufacturing platform and emerging partnerships around RNA-targeted medicines extends the story into manufacturing efficiency and non-liver applications, which are not fully reflected in the original focus on cardiomyopathy launches and near-term rare disease assets.  Knowing what a company is worth starts with understanding its story.\nCheck out one of the top narratives in the Simply Wall St Community for Alnylam Pharmaceuticals to help decide what it's worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Heavy reliance on the TTR franchise means setbacks in ATTR-CM or competing approaches from peers in rare disease and cardiology could hit revenue and profitability disproportionately. ⚠️ Continued high R&D and commercial spending, plus a US$2.26b shelf registration, points to ongoing capital needs that could lead to share issuance or pressure on returns if new programs do not scale as planned. 🎁 First-time profitability, with quarterly revenue of US$1.10b and a swing from a US$83.76 million loss to US$111.54 million net income, shows the existing portfolio can fund further RNAi development. 🎁 New RNA-focused partnerships and a dedicated RNAi manufacturing platform may widen Alnylam’s opportunity set versus other RNA and rare disease players such as Ionis Pharmaceuticals and Moderna by supporting new indications and potentially more efficient production.  What To Watch Going Forward From here, you may want to watch how much of Alnylam’s revenue and profit growth continues to come from Amvuttra and the broader TTR franchise versus newer programs, including any RNA-targeted small-molecule collaborations. Progress on the new manufacturing platform will be worth tracking, especially if management starts to quantify cost savings or capacity gains. It is also useful to keep an eye on how large-cap rivals in RNA and cardiometabolic disease position their own therapies, as competitive outcomes could influence pricing, access and the durability of Alnylam’s earnings profile. To ensure you're always in the loop on how the latest news impacts the investment narrative for Alnylam Pharmaceuticals, head to the\ncommunity page for Alnylam Pharmaceuticals to never miss an update on the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}